EHA 2019: Acalabrutinib Shows Remarkable Benefit in Relapsed or Refractory CLL

Paolo Ghia | EHA 2019 | Juni 17, 2019

Föreläsare: Paolo Ghia

In this MEDtalk The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed or refractory CLL are presented for the first time at EHA. In this study, acalabrutinib monotherapy significantly improved PFS with a more tolerable safety profile, compared with idelalisib/ bendamustine in patients with relapsed or refractory CLL, reducing the risk of disease progression or death by 69% after 16.1 months.